Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Post Market

Current status date:

2018-04-05

Original market date: See footnote 1

2008-04-24

Lot number: See footnote 2

270PP3N

Expiry date: See footnote 2

2017-03-24

Product name:

HELIXATE FS

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02243188

Product Monograph/Veterinary Labelling:

Date: 2014-07-04 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

BAYER HEALTHCARE LLC
100 Bayer Boulevard
Whippany
New Jersey
United States 07981

Class:

Human

Dosage form(s):

Powder For Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

1

Schedule(s):

Schedule D

 

American Hospital Formulary Service (AHFS): See footnote 3

20:28.16 

Anatomical Therapeutic Chemical (ATC): See footnote 4

B02BD02 COAGULATION FACTOR VIII

Active ingredient group (AIG) number:See footnote5

0124180002

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
ANTIHEMOPHILIC FACTOR (RECOMBINANT) 1000 UNIT / VIAL
Version 4.0.3

"Page details"

Date modified: